Avita Medical Ltd. (OTC: AVMXY) develops and distributes regenerative products to treat a broad range of wounds, scars and skin defects. The company’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. Its lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device; a pivotal U.S. trial is underway, with patient enrollment completion anticipated by year-end. For more information, visit the company’s website at www.avitamedical.com.